$XBI $128 -1%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$BNTX +3% Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents. source
$HGEN -11% Humanigen Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19. source
$OMER +3% OMEROS ANNOUNCES PRELIMINARY RESULTS FROM ADDITIONAL CRITICALLY ILL COVID-19 PATIENTS TREATED WITH NARSOPLIMAB. source
Pipeline Updates
$BBIO +2% bridgebio pharma’s affiliate qed therapeutics and partner helsinn group announce fda approval of truseltiq™ (infigratinib) for patients with cholangiocarcinoma. source
$LMNL -1% Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras. source
$CALT +1% Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency. source
$ETON -20% Eton Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Dehydrated Alcohol Injection. source
$AZN -1% Tagrisso approved in the EU for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer. source
$PRVB -28% FDA Advisory Committee Votes in Favor of the Benefits of Teplizumab Outweighing the Risks in Support of Approval to Delay Clinical Type 1 Diabetes (T1D). source
Financial Updates
$ADMS +10% Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ. source
Posted by DV